Introduction
============

Globally, an estimated 366.2 million people with diabetes existed in 2011, accounting for 8.3% of the world adult population, and this number is projected to increase to 551.8 million by 2030, which would represent 9.9% of world adult population[@b1]. In South East Asia, 71.4 million people had diabetes in 2011, and this number is estimated to increase to 120.9 million in 2030[@b1]. The prevalence of diabetes in Korea is set to increase from its level of 3.3 million in 2010 to 4.3 million by 2030[@b2]. In the past four decades, the prevalence of diabetes in Korea has increased from 1.5 to 9.9%[@b3]. A nationwide survey of Korean patients with diabetes reported a high prevalence of diabetic complications, such as microalbuminuria (30.3%), retinopathy (38.3%), nephropathy (44.6%), coronary artery disease (CAD; 8.7%), cerebrovascular disease (CVD; 6.7%) and peripheral artery disease (PAD; 3.0%)[@b4]. The increasing prevalence of diabetes mellitus and its related complications have contributed to a substantial increase in morbidity and mortality in Korea[@b5].

The international guidelines, including American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) guidelines[@b6], the American Association of Clinical Endocrinologists/American College of Endocrinology Diabetes Guidelines (AACE/ACE) guidelines[@b7] and the Korean national guidelines[@b8], suggest comprehensive management of patients with type 2 diabetes to maintain glycemic control, and reduce the risk of microvascular and macrovascular diabetes-related complications. According to the algorithm for medical management of type 2 diabetes, the ADA/EASD guidelines recommend initial therapy with lifestyle changes and then use of metformin (Met), followed by continuing timely augmentation of therapy with additional agents (including sulfonylureas \[SU\] and early initiation of insulin therapy)[@b6]. Both Met and SU have been widely used[@b9]. The combination of Met and SU (Met + SU) addresses both underlying defects in the disorder, insulin deficiency and insulin resistance. Earlier randomized controlled trials on Met + SU combination showed significant reductions in glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes not controlled by monotherapy alone[@b10],[@b11]. However, the results of these studies should be validated in the real-world practice, outside the controlled conditions of the randomized trials.

Evaluation of glycemic control in patients with type 2 diabetes receiving Met + SU would be very relevant for planning further treatment intensification strategies targeting improved diabetes control. However, there is a paucity of real-world data on the effect of Met + SU in type 2 diabetes patients in Korea. The Observational Registry Study to Explore the Current status of Glucose Control in type 2 Diabetes Mellitus Patients on Oral Hypoglycemic Agents in Real Practice (HbA1c Level in Type 2 Diabetes Patients on Oral Hypoglycemic Agents \[ALIT\]) study in Korea aimed to evaluate the current status of glycemic control in patients with type 2 diabetes receiving Met + SU therapy.

Materials and Methods
=====================

Study Design and Objective
--------------------------

It was a multicenter, non-interventional, cross-sectional observational study carried out in 299 centers across Korea. The objective of the study was to explore the current status of glucose control in patients with type 2 diabetes receiving Met + SU, by assessing the HbA1c levels.

The present study was carried out in accordance with the Declaration of Helsinki (as revised in Edinburgh 2000)[@b12] and all subsequent amendments, and guidelines for Good Epidemiological Practice in the USA[@b13] and Europe[@b14]. The protocol was approved by the local ethics committees at each study site.

Investigators
-------------

The participating physicians were selected to obtain stratified physician groups from general hospitals, semi-hospitals and clinics. They included endocrinologists, internists and other primary care physicians. In context of the present study, endocrinologists were defined as members of the Korean Endocrine Society, and mainly worked in tertiary and secondary hospitals. Internists were defined as members of the Korean Association of Internal Medicine, and worked as primary care physicians. Other primary care physicians included general practitioners, including family physicians, and all doctors other than endocrinologists and internists.

Patients
--------

The study included patients diagnosed with type 2 diabetes, who were being treated with Met + SU for \>3 months, who had their HbA1c levels tested within the past 1 month before enrolment and who signed the data release consent form before the study. Exclusion criteria comprised patients who were participating in another clinical study, who received insulin within 3 months, and who had taken oral hypoglycemic agents other than SU and Met within the past 3 months.

Study Assessments
-----------------

Data collected included patient demographics: diabetic complications (retinopathy, neuropathy, nephropathy, microalbuminuria, cardiovascular disease \[CVD\] and peripheral vascular disease \[PVD\]); diabetic comorbidities (hypertension, dyslipidemia related to total cholesterol \[TC\], low-density lipoprotein \[LDL\], high-density lipoprotein \[HDL\] and triglycerides \[TG\]); duration of diabetes; and HbA1c levels, fasting blood glucose (FBG) levels, fasting plasma glucose (FPG) levels and treatment details with oral hypoglycemic agents. Whether the patient had diabetic complications was identified by review of the patient\'s medical records.

As per the post-hoc analysis, we analyzed three subgroups of patients who were treated by: (i) endocrinologists; (ii) internists; and (iii) other primary care physicians.

Statistical Analysis
--------------------

Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were expressed as frequencies and percentages. The average HbA1c values were summarized by mean ± SD, median, minimum and maximum levels. Statistical methods used included analysis of the variance ([anova]{.smallcaps}) χ^2^-test, Wald χ^2^-test and *t*-test. The univariate and multivariate logistic regression analyses were carried out to test associations between patient characteristics and achievement of target HbA1c. All statistical tests were carried out using two-tailed tests at 5% level of significance or with adjustment if required. All statistical analyses were carried out using [sas]{.smallcaps} version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient Disposition
-------------------

Between April 2008 and February 2009, a total of 5692 patients were enrolled. Of them, 5628 patients, excluding 64 patients who did not meet the eligibility criteria, were included in the analysis.

Met + SU Treatment Received By Patients
---------------------------------------

Of the total patients, 1,457 (25.9%) patients received fixed-dose combination of Met + SU in one pill. There were very few patients who received the following combination of treatment: SU + fixed-dose combination of Met + SU (41, 0.7%), Met + fixed dose combination of Met + SU (63, 1.1%) and SU + Met + fixed dose combination of Met + SU (11, 0.2%),

Patient Characteristics in Total Patients and Subgroups of Patients Treated By Different Physician Specialties
--------------------------------------------------------------------------------------------------------------

Table[1](#tbl1){ref-type="table"} presents data on patient characteristics, diabetic complications and comorbidities of total patients, as well as patient subgroups treated by different physician specialties. Of 5,628 patients, 3,099 (55.1%) were males. Mean age and body mass index (BMI) were 58.4 ± 10.8 years and 24.7 ± 2.9 kg/m^2^, respectively. Mean HbA1c was 7.8 ± 1.2%, FBG was 147.3 ± 46.5 mmol/L and FPG was 164.0 ± 54.3 mmol/L. Diabetic neuropathy (22.5%) was the most common diabetic complication, whereas hypertension (59.2%) was the most common comorbidity. Mean duration of diabetes in total patients was 6.1 ± 4.7 years, whereas mean time to start combination therapy after diagnosis was 1256.9 ± 1424.2 days (mean time to start combination therapy in patients visiting endocrinologists, internists and other primary care physicians was 1311.2 ± 1510.5 days, 1226.2 ± 1327.0 days and 1406.2 ± 2,305 days, respectively (*P* = 0.3590).

###### 

Characteristics of three subgroups of patients and total patients

  Characteristics                        Departments    Total          *P*-value                     
  -------------------------------------- -------------- -------------- -------------- -------------- -------------------------------------------
  Sex                                                                                                
   *n*                                   1,848          3,586          194            5,628          
   Male                                  976 (52.8)     2,016 (56.2)   107 (55.2)     3,099 (55.1)   0.0574[\*](#tf1-5){ref-type="table-fn"}
   Female                                872 (47.2)     1,570 (43.8)   87 (44.9)      2,529 (44.9)   
  Age (years)                                                                                        
   *n*                                   1,848          3,586          194            5,628          
   Mean ± SD                             57.9 ± 11.0    58.6 ± 10.5    59.7 ± 13.1    58.4 ± 10.8    0.0322[†](#tf1-6){ref-type="table-fn"}
  Duration of diabetes (years)                                                                       
   *n*                                   1,598          3,336          117            3,609          
   Mean ± SD                             6.5 ± 5.4      5.9 ± 4.2      7.0 ± 6.7      6.1 ± 4.7      \<0.0001[\*](#tf1-5){ref-type="table-fn"}
  Weight (kg)                                                                                        
   *n*                                   1,451          3,188          173            4,812          
   Mean ± SD                             66.2 ± 11.0    66.7 ± 10.1    65.2 ± 11.4    66.5 ± 10.5    0.0702[†](#tf1-6){ref-type="table-fn"}
  Waist circumference (cm)                                                                           
   *n*                                   1,043          2,359          115            3,517          
   Mean ± SD                             87.6 ± 9.3     89.7 ± 11.3    87.2 ± 10.3    89.0 ± 10.8    \<0.0001[†](#tf1-6){ref-type="table-fn"}
  BMI (kg/m^2^)                                                                                      
   *n*                                   1,443          3,156          172            4,771          
  Mean ± SD                              24.8 ± 3.1     24.7 ± 2.7     24.6 ± 3.7     24.7 ± 2.9     0.2096[†](#tf1-6){ref-type="table-fn"}
  HbA1c levels (%)                                                                                   
   *n*                                   1,848          3,586          194            5,628          
   Mean ± SD                             7.6 ± 1.3      7.8 ± 1.1      8.1 ± 1.6      7.8 ± 1.2      \<0.0001[†](#tf1-6){ref-type="table-fn"}
  FBG (mg/dL)                                                                                        
   *n*                                   862            1,740          137            2,739          
   Mean ± SD                             142.2 ± 38.8   149.2 ± 47.3   156.2 ± 71.2   147.3 ± 46.5   0.0001[†](#tf1-6){ref-type="table-fn"}
  FPG (mg/dL)                                                                                        
   *n*                                   600            1,203          36             1,839          
   Mean ± SD                             158.2 ± 52.1   166.5 ± 54.7   176.9 ± 67.8   164.0 ± 54.3   0.0033[†](#tf1-6){ref-type="table-fn"}
  Prevalence of complications                                                                        
   Diabetic retinopathy                                                                              
    *n*                                  1,608          3,058          165            4,831          
    *n* (%)                              362 (22.5)     497 (16.3)     24 (14.6)      883 (18.3)     \<0.0001[\*](#tf1-5){ref-type="table-fn"}
   Diabetic neuropathy                                                                               
    *n*                                  1,655          3,233          181            5,069          
    *n* (%)                              383 (23.1)     727 (22.5)     32 (17.7)      1,142 (22.5)   0.2468[\*](#tf1-5){ref-type="table-fn"}
   Diabetic nephropathy                                                                              
    *n*                                  1,663          3,030          178            4,871          
    *n* (%)                              188 (11.3)     406 (13.4)     13 (7.3)       607 (12.5)     0.0121[\*](#tf1-5){ref-type="table-fn"}
   Microalbuminuria                                                                                  
    *n*                                  1,629          2,696          156            4,481          
    *n* (%)                              326 (20.0)     380 (14.1)     14 (9.0)       720 (16.1)     \<0.0001[\*](#tf1-5){ref-type="table-fn"}
   CVD[‡](#tf1-7){ref-type="table-fn"}                                                               
    *n*                                  1,599          2,973          183            4,755          
    *n* (%)                              215 (13.5)     311 (10.5)     21 (11.5)      547 (11.5)     0.0106[\*](#tf1-5){ref-type="table-fn"}
   PVD                                                                                               
    *n*                                  1,493          2820           177            4,490          
    *n* (%)                              105 (7.0)      64 (2.3)       2 (1.1)        171 (3.8)      \<0.0001[\*](#tf1-5){ref-type="table-fn"}
  Prevalence of comorbidities                                                                        
   Hypertension                                                                                      
    *n*                                  1,747          3,417          186            5,350          
    *n* (%)                              890 (50.9)     2,158 (63.2)   121 (65.1)     3,169 (59.2)   \<0.0001[\*](#tf1-5){ref-type="table-fn"}
   High TC                                                                                           
    *n*                                  1,608          3,219          171            4,998          
    *n* (%)                              299 (18.6)     975 (30.3)     40 (23.4)      1,314 (26.3)   \<0.0001[\*](#tf1-5){ref-type="table-fn"}
   High LDL                                                                                          
    *n*                                  1,536          2,952          149            4,637          
    *n* (%)                              494 (32.2)     989 (33.5)     54 (36.2)      1,537 (33.2)   0.4757[\*](#tf1-5){ref-type="table-fn"}
   Low HDL                                                                                           
    *n*                                  1,528          2,950          148            4,626          
    *n* (%)                              440 (28.8)     707 (24.0)     34 (23.0)      1,181 (25.5)   0.0016[\*](#tf1-5){ref-type="table-fn"}
   High TG                                                                                           
    *n*                                  1,585          3,064          164            4,813          
    *n* (%)                              529 (33.4)     1,165 (38.0)   60 (36.6)      1,754 (36.4)   0.0077[\*](#tf1-5){ref-type="table-fn"}

FBG, fasting blood glucose; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; SD, standard deviation.

*n* = 5,628.

Missing data -- weight: 816; waist circumference: 2111; body mass index (BMI): 857; diabetic retinopathy: 797; diabetic neuropathy: 557; diabetic nephropathy: 757; micro-albuminuria: 1147; cardiovascular disease (CVD): 873; peripheral vascular disease (PVD): 1,138; hypertension: 258; total cholesterol (TC): 630; low-density lipoprotein (LDL): 991; high-density lipoprotein (HDL): 1,002; TG: 815.

Cut-offs used -- hypertension: blood pressure \>130/80 mmHg; High TC: \>240 mg/dL (6.1 mmol/L); High LDL: \>100 mg/dL (2.5 mmol/L); high HDL: in males \<40 mg/dL (1.0 mmol/L), in females \<50 mg/dL (1.2 mmol/L); high triglycerides (TG): \>150 mg/dL (1.6 mmol/L).

χ^2^-test.

Analysis of variance test.

Angina/myocardial infarction/chronic heart failure/stroke.

Achievement of Target HbA1c
---------------------------

Data on target HbA1c achievement is presented in Figure[1](#fig01){ref-type="fig"}. Just 27.1% of patients achieved HbA1c ≤7%. A higher number of patients (32.6%) treated by endocrinologists achieved HbA1c ≤7% than those treated by internists (24.4%) and other primary care physicians (23.2%; *P* \< 0.0001).

![Achievement of target glycosylated hemoglobin (HbA1c) in subgroup and total patients (χ^2^ *P*-value \<0.0001).](jdi0006-0317-f1){#fig01}

Levels of HbA1c and Patient Characteristics
-------------------------------------------

The details of HbA1c levels as per patient characteristics are presented in [Table S1](#sd1){ref-type="supplementary-material"}. Young age, long duration of diabetes, diabetic retinopathy, nephropathy, dyslipidemia related to total cholesterol, LDL and triglycerides were significantly associated with high HbA1c.

Factors Associated With HbA1c Target Achievement (HbA1c ≤7%) by Univariate and Multivariate Analysis
----------------------------------------------------------------------------------------------------

The strength and statistical significance of the association of patient characteristics with achievement of target HbA1c, as tested by univariate and multivariate logistic regression, is presented in Table[2](#tbl2){ref-type="table"}. Findings of this analysis show that patients with older age added by 1 year significantly increased chances of achieving target HbA1c (adds ratio \[OR\] 1.019, 95% confidence interval \[CI\] 1.01--1.029). The presence of diabetic retinopathy (OR 0.455, 95% CI 0.341--0.606), nephropathy (OR 0.639, 95% CI 0.43--0.949) and diabetes for ≥5 years (OR 0.493, 95% CI 0.4--0.606) significantly decreased the odds of achieving target HbA1c.

###### 

Factors associated with glycosylated hemoglobin target achievement by univariate and multivariate analysis

                                                     Unadjusted OR (95% CI)   *P*-value[a](#tf2-3){ref-type="table-fn"}   Adjusted OR (95% CI)   *P*-value[b](#tf2-4){ref-type="table-fn"}
  -------------------------------------------------- ------------------------ ------------------------------------------- ---------------------- -------------------------------------------
  Sex (male/female)                                  1.115 (0.99--1.255)      0.0721                                                             
  Age (per 1 year higher)                            1.01 (1.005--1.016)      0.0003[\*](#tf2-3){ref-type="table-fn"}     1.019 (1.01--1.029)    \<0.0001
  BMI (per 1 kg/m^2^ higher)                         1.025 (1.003--1.048)     0.0263[\*](#tf2-3){ref-type="table-fn"}                            
  Abdominal circumference (per 1 cm higher)          0.998 (0.991--1.005)     0.5450[\*](#tf2-3){ref-type="table-fn"}                            
  Diabetic retinopathy (yes vs no)                   0.537 (0.447--0.646)     \<0.0001                                    0.455 (0.341--0.606)   0.0001
  Diabetic neuropathy (yes vs no)                    0.911 (0.785--1.056)     0.2147                                                             
  Diabetic nephropathy (yes vs no)                   0.524 (0.422--0.65)      \<0.0001                                    0.639 (0.43--0.949)    0.0104
  Microalbuminuria (yes vs no)                       0.867 (0.722--1.041)     0.1259                                                             
  CVD (yes vs no)                                    0.797 (0.65--0.978)      0.0294                                                             
  PVD (yes vs no)                                    0.524 (0.352--0.782)     0.0013                                                             
  Hypertension (yes vs no)                           0.947 (0.839--1.07)      0.3834                                                             
  Dyslipidemia high TC (yes vs no)                   0.683 (0.59--0.791)      \<0.0001                                                           
  Dyslipidemia high LDL (yes vs no)                  0.925 (0.806--1.061)     0.2658                                                             
  Dyslipidemia low HDL (yes vs no)                   0.97 (0.837--1.126)      0.6911                                                             
  Dyslipidemia high TG (yes vs no)                   0.945 (0.829--1.078)     0.4002                                                             
  Duration of diabetes (≥5 years vs \<5 years)       0.522 (0.462--0.591)     \<0.0001                                    0.493 (0.4--0.606)     \<0.0001
  Physician groups                                                                                                                               
   Endocrinology vs family medicine and others       1.604 (1.133--2.270)     0.0077                                                             
   Endocrinology vs internal medicine                1.498 (1.324--1.695)     \<0.0001                                    1.417 (1.146--1.751)   0.0013
   Internal medicine vs family medicine and others   1.070 (0.760--1.507)     0.6971                                                             

BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; HbA1c, glycosylated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; Met, metformin; OR, odds ratio; PVD, peripheral vascular disease; SD, standard deviation; SU, sulfonylurea; TC, total cholesterol; TG, triglycerides.

*n* = 5,628.

*P*-value: \*Unpaired *t*-test; the rest of the values are by χ^2^-test.

*P*-value: Wald χ^2^-test.

When comparisons were made among the physician subgroups, patients being treated by endocrinologists had significant increased chances of achieving target HbA1c.

Discussion
==========

In the present large, multicenter, cross-sectional observational study of patients with type 2 diabetes receiving Met + SU treatment in Korea, we observed that just 1,524 (27.1%) patients achieved target HbA1c (≤7%). According to earlier studies in Korea, the percentage of treated patients with type 2 diabetes who achieved target HbA1c \<7% was in the range of 35.7--43.5%[@b4],[@b15],[@b16]. The present results suggest that almost three-quarters of patients with type 2 diabetes were not well controlled, despite being treated with Met + SU therapy. We also found that young age and diabetic complications, such as retinopathy, nephropathy and long duration of diabetes, were associated with a decreased chance of achieving target HbA1c. These data, which report underachievement of target HbA1c in treated patients, serve as an alert to physicians, and emphasize the need to prescribe intensive treatment for diabetes management.

Type 2 diabetes is an increasing epidemic in Asia, characterized by rapid rates of increase over short periods, onset at a relatively young age and low BMI[@b17]. Patient characteristics of Korean patients with type 2 diabetes are known to be different than patients from Western countries. The low BMI in the present study (24.7 kg/m^2^) is comparable with a previous study reporting 60--80% of Korean patients having type 2 diabetes with BMI \<25 kg/m^2^ [@b18]. We found that BMI (OR 1.002, 95% CI 0.964--1.041, *P* = 0.7039) and abdominal circumference (OR 0.994, 95% CI 0.983--1.005, *P* = 0.2866) were not significantly associated with achievement of target HbA1c. In the present study, young age (OR 1.019, 95% CI 1.01--1.029, *P* \< 0.0001) has been shown to be associated with decreased chances of achieving target HbA1c. Young patients have been associated with low glycemic control as compared with old patients, which might be due to the fact that young patients are less compliant with recommendations of diet, exercise and pharmacological treatment[@b19].

In Asian patients with type 2 diabetes, diabetes is associated with high rates of cardiovascular risk factors, leading to high morbidity, mortality and economic burden. Earlier studies in Korea reported chronic complications in patients with type 2 diabetes. A cross-sectional study in Korea of patients admitted to hospital reported a high prevalence of CVD (7.8%), stroke (8.4%) and retinopathy (35.2%)[@b20]. A study showed a high prevalence of hypertension (43.2%), dyslipidemia (34.8%), macrovascular disease (10.8%) and microvascular disease (16.7%)[@b21]. In another study, there was a high prevalence of complications: microalbuminuria 30.3%, retinopathy 38.3%, nephropathy 44.6%, CAD 8.7%, CVD 6.7% and PAD 3.0%[@b4]. The prevalence of diabetic complications in the present study is in line with the earlier studies; that is, neuropathy 22.5%, retinopathy 18.3%, microalbuminurea 16.1%, nephropathy 12.5%, CVD 11.5% and PVD 3.8%. The prevalence of comorbidities in our studies is high: hypertension 59.2%, high TG 36.4%, high LDL 33.2% and low HDL 33.2%. The present study also showed that patients with diabetic complications, such as retinopathy, nephropathy and long duration of diabetes, were significantly associated with a decreased chance of achieving target HbA1c, which is in line with an earlier study[@b22].

Hence, reducing the diabetes complications should be a public health priority in Asian populations[@b17]. Earlier studies, including the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), have shown the importance of strict glycemic control to prevent and/or reduce the risk of these complications[@b23],[@b24]. In the ALIT study, the majority of patients (72.9%) did not achieve HbA1c ≤7%, despite receiving Met + SU treatment. The reported inadequate metabolic control in these patients suggests that current treatment regimens might be insufficient to reach glycemic target. Early and persistent intensification of antidiabetic therapy is an approach that most likely will achieve optimal glycemic control in patients with type 2 diabetes and help prevent associated complications[@b25]. According to the Korean guidelines, another oral hypoglycemic agent (OHA) is added to existing OHA, if patients do not reach the HbA1c target. However, in the current study, the time to start combination therapy after diagnosis is approximately 3.5 years. This can be due to the clinical inertia in up-titration of treatment dose and initiation of additional therapies, which could lead to suboptimal glycemic control rates[@b26]. In an earlier study, 45.1% of patients with specialist care were prescribed drug intensification vs 37.4% with primary care physician (*P* = 0.009)[@b27].

The present study reports that mean HbA1c in patients visiting endocrinologists, internists and other primary care physicians was 7.6, 7.8 and 8.1%, respectively (*P* \< 0.0001). Earlier studies also reported that patients treated by endocrinologists showed significantly lower HbA1c levels than that patients visiting primary care units (8.3% vs 8.7%, *P* = 0.01)[@b28], (7.9% vs 8.3%, *P* \< 0.0001)[@b27]. As aforementioned, this result could partly reflect a lack of drug intensification in primary care units. Therefore, the same prescriptions between specialist care and primary care are important for this kind of comparison. In the present study, despite the same Met + SU prescriptions, achievement of target HbA1c with endocrinologists was significantly better than that with internists or other primary care physicians; that is, 32.6% of patients treated by endocrinologists achieved target HbA1c, as compared with 24.4% of patients treated by internists and 23.2% of patients treated by other primary care physicians. On the contrary, an earlier study in Japanese patients with type 2 diabetes showed that the proportion of patients treated by general practitioners with HbA1c levels \<6.5% and \<7.0% were 43.1% and 62.7%, respectively, whereas for the patients treated by specialists, the proportions were 36.2 and 56.4%, respectively[@b29]. One of the possible explanations for this result is that the phenotype of patients with diabetes was different between hospitals and primary care units. Therefore, patients cared by specialists might have more severe diabetes. In the present study, patients visiting endocrinologists had more diabetic complications compared with patient visiting internists and other primary care physicians (Table[1](#tbl1){ref-type="table"}).

It has also been observed that the proportion of patient visits meeting the minimally acceptable levels of quality was better in the diabetes clinic than the general medicine clinic (73% vs 52%, *P* = 0.02)[@b30]. Although the mean duration of diabetes in patients treated by endocrinologists is 6.5 years, as compared with those treated by internists (5.8 years) and other primary care physicians (7.0 years), the proportion of comorbidities reported in the patients treated by endocrinologists were less than the other two groups.

This was a large observational study that enrolled patients from 299 centers across Korea. To the best of our knowledge, this is the largest nationwide study to provide real-life data on glycemic control in type 2 diabetes patients treated with Met + SU antidiabetic treatment in Korea.

However, the present study also had some limitations. In this observational study, there could be bias in hospital selection and potential confounders if any. Another limitation was the cross-sectional nature of the study, which did not allow long-term follow up in terms of further intensification of antidiabetic therapy. The measurements of lipid profile and other clinical measurements were carried out in different laboratories/hospitals, hence there can be interlaboratory variations in the measurements. The present study did not collect data on any self-monitoring of blood glucose by patients. In addition, our study evaluated two specific OHAs, Met and SU, and did not collect information on the dosage of each medication. Also, the study did not collect data on adherence/compliance to the Met + SU treatment for controlling glycemia.

In conclusion, the majority of patients with type 2 diabetes in Korea have inadequate glycemic control, despite receiving Met + SU. Intensification of antihyperglycemic therapy is necessary to ensure optimal glycemic control in patients with type 2 diabetes in Korea. Therefore, future longitudinal studies to assess glycemic control in Korean patients over various time durations after starting/intensifying treatments are warranted.
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**Table S1\|** Glycosylated hemoglobin levels according to patient characteristics (*n* = 5,628)
